Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$47 Mln
P/E Ratio
--
P/B Ratio
5.74
Industry P/E
--
Debt to Equity
0.55
ROE
-1.59 %
ROCE
-120.38 %
Div. Yield
0 %
Book Value
1.08
EPS
-1.7
CFO
$-195.78 Mln
EBITDA
$-222.10 Mln
Net Profit
$-234.22 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Electrocore LLC (ECOR)
| -59.35 | -17.63 | -59.09 | 17.26 | -3.51 | -17.93 | -- |
|
BSE Sensex*
| 2.14 | 3.92 | 4.44 | 8.38 | 11.80 | 20.19 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Electrocore LLC (ECOR)
| 170.13 | 54.55 | -55.87 | -62.63 | -1.89 | -74.60 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.47 | 10,289.47 | 14.38 | 12.69 | |
| 71.79 | 9,544.04 | 92.52 | 2.52 | |
| 278.77 | 10,728.90 | 773.26 | 1.2 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation ("nVNS") technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a... prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey. Address: 200 Forge Way, Rockaway, NJ, United States, 07866 Read more
CEO & Director
Mr. Daniel S. Goldberger
CEO & Director
Mr. Daniel S. Goldberger
Headquarters
Rockaway, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Electrocore LLC (ECOR) stood at $ 20 Mln as on 31-Dec-24
The share price of Electrocore LLC (ECOR) is $6.59 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Electrocore LLC (ECOR) has given a return of -3.51% in the last 3 years.
Electrocore LLC (ECOR) has a market capitalisation of $ 47 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Electrocore LLC (ECOR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Electrocore LLC (ECOR) and enter the required number of quantities and click on buy to purchase the shares of Electrocore LLC (ECOR).
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation ("nVNS") technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey. Address: 200 Forge Way, Rockaway, NJ, United States, 07866
The CEO & director of Mr. Daniel S. Goldberger. is Electrocore LLC (ECOR), and CFO & Sr. VP is Mr. Daniel S. Goldberger.
There is no promoter pledging in Electrocore LLC (ECOR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,070
|
|
|
1,049
|
|
|
978
|
| Electrocore LLC (ECOR) | Ratios |
|---|---|
|
Return on equity(%)
|
-158.63
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-47.2
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Electrocore LLC (ECOR) was $0 Mln.
$0.04
(
